Allay Therapeutics Establishes Corporate Headquarters in the Bay Area and Expands Base of Operations in Singapore

MENLO PARK, Calif.–(BUSINESS WIRE)–Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that it has established its corporate headquarters in San Jose, California and expanded its base of operations in Singapore.

The new headquarters, located at BioSquare, a Silicon Valley life sciences park in North San Jose, will house administrative, research and development, clinical and operations functions supporting Allay�s technology platform and product development pipeline. The 50,000 square foot Allay headquarters will accommodate Allay’s global workforce, which has nearly doubled over the last year, and its planned growth in the U.S. and Singapore. Allay also doubled its Singapore footprint with the renewal and expansion of its R&D and operations facilities in the Singapore Science Park, a leading life sciences and innovation campus. Allay plans to occupy both the U.S. site and the expanded Singapore facility by spring 2022 and complete the build-out of laboratory space in its headquarters by fall 2022.

“We’re pleased to establish a permanent presence in the talent-rich Bay Area and to expand the global facilities supporting the burgeoning pipeline led by our Singapore based team members. The new headquarters is designed to enable full integration of our research, manufacturing and pipeline development activities across our global teams, and is a testament to our significant growth as a company over the last year,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics. “We’re grateful for the continued support of our investor group and our medical advisors, and believe we are well positioned to advance revolutionary pain management products from our pipeline supported by a growing world-class team with cutting-edge facilities and technology.”

About Allay Therapeutics

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture’s Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com.

Contacts

Investors
Adam Gridley

adam.gridley@allaytx.com

Media
Chris Railey

chris@tenbridgecommunications.com
M: +1 617-834-0936